STOCK TITAN

MediPharm Labs Sets Date to Report Third Quarter 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) will release its Q3 financial results for the three and nine month periods ended September 30, 2023 on November 14, 2023. The executive team will host a conference call and webcast to discuss the results.
Positive
  • None.
Negative
  • None.

TORONTO, Nov. 8, 2023 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its third quarter financial results for the three and nine month periods ended September 30, 2023, before markets open on Tuesday, November 14, 2023.

MediPharm's executive management team will also host a conference call and audio webcast on Tuesday, November 14, 2023 at 8:30 a.m. eastern time to discuss the Company's financial results.

Audio Conference Call Dial in Details:

Toll-free number: +1 (888) 330-2454 / International number: +1 (240) 789-2714

Conference ID: 4921762

Participants are asked to dial in approximately 15 minutes before the start of the call.

Audio Webcast:              

An audio webcast will be available by visiting the following link here.

For those who are unable to participate on the live conference call or webcast, a replay will be available at https://www.medipharmlabs.com/investors approximately one day after completion of the call.                

About MediPharm Labs 

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing Licence for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website a www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-sets-date-to-report-third-quarter-2023-financial-results-301982359.html

SOURCE MediPharm Labs Corp.

FAQ

What is the ticker symbol of MediPharm Labs Corp.?

The ticker symbol for MediPharm Labs Corp. is TSX: LABS, OTCQB: MEDIF, and FSE: MLZ.

When will MediPharm Labs Corp. release its Q3 financial results?

MediPharm Labs Corp. will release its Q3 financial results on November 14, 2023.

How can I access the audio webcast of the conference call?

The audio webcast will be available by visiting the link provided in the press release.

Where can I find the replay of the conference call and webcast?

The replay will be available at https://www.medipharmlabs.com/investors approximately one day after the completion of the call.

MEDIPHARM LABS CORP

OTC:MEDIF

MEDIF Rankings

MEDIF Latest News

MEDIF Stock Data

20.54M
382.53M
4.45%
0.71%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Barrie